Effectiveness and safety of upadacitinib in patients with face and neck atopic dermatitis unresponsive to dupilumab

Click to increase image sizeClick to decrease image size

Disclosure statement

None.

Ethics statement

The patients in this manuscript have given written informed consent to the publication of their case details.

Data available statement

Data available on request from the authors.

Additional information

Funding

This research is supported by the Guangzhou Basic Research Program Joint Funding Project for Municipal and University/Institute Collaboration(SL2022A03J00249).